Frozen shoulder causes significant functional disability and pain in a population group constituted by patients who are often middle-aged and working.

Frozen shoulder remains poorly understood. The available literature is limited and often prone to bias.

A rapid, non-surgical and cost-effective treatment that reduces pain and restores function is an attractive option.

Hydrodilatation is a potential first-line treatment of frozen shoulder in secondary care.

Keywords: frozen shoulder; aetiology; pathogenesis; conservative treatment; operative treatment; hydrodilatation

Indications for hydrodilatation for frozen shoulder

S. Rymaruk1
C. Peach1

Hydrodilatation has emerged as a potential non-surgical option in the management of frozen shoulder. However, its role has yet to be fully clarified. There are unanswered questions relating to its use in diabetic patients. The role of hydrodilatation compared with more established treatments for frozen shoulder remains undefined.

The frozen shoulder

In 1934 Codman1 described the clinical picture of frozen shoulder with an insidious onset of lateral shoulder pain with restriction in active and passive movement. Codman acknowledged the challenge in definition and treatment of the disease, which still remains today.2,3

Frozen shoulder classically occurs in female patients in their fourth to sixth decade of life and can be classified according to its presumed aetiology into primary idiopathic or secondary. Secondary frozen shoulder can be further categorised into that from intrinsic causes such as rotator cuff pathology, extrinsic causes such as humeral fractures, or systemic causes such as diabetes and thyroid dysfunction. The incidence of frozen shoulder in the background population is up to 5%, but in diabetics can be up to 20%.4

A recent study has supported a potential link between Propionibacterium (P.) acnes and frozen shoulder as a possible infective aetiology of the disease.5 In this study ten patients undergoing arthroscopic arthrolysis underwent tissue biopsies, of which 60% were positive for P. acnes. This led the authors to question whether ‘P. acnes could be the Helicobacter of frozen shoulder’.5

The patho-aetiology of frozen shoulder is, however, complex and multifactorial with both genetic and environmental factors playing an important role.6

Frozen shoulder progresses in a cyclical manner, beginning with a painful ‘freezing’ phase which is characterised by hypervascularity seen during arthroscopy. The freezing (stiffening) stage lasts about three months. The disease then progresses to a painless ‘frozen’ phase which can last up to nine months, where marked restriction of movement is the predominant feature. Finally the disease progresses to a ‘thawing’ phase with remodelling, and patients begin to report an improvement in range of movement. This can last up to 18 months. The latter stages demonstrate significant capsular thickening with contraction which can be demonstrated clinically with loss of external rotation visualised during MRI or arthroscopy. The stage of the disease process that the patient is in may influence treatment, with steroid therapy preferred in the freezing phase whilst arthroscopic arthrolysis may be preferred in the frozen phase.

Historically patients were reassured that a complete recovery was inevitable; however, the evidence to support this is variable. In 1978, Grey7 reported on 24 of 25 patients who improved with conservative treatment or observation over a two-year period. Another study with an average of nine-year follow-up data for patients with frozen shoulder reported 94% rate of spontaneous complete recovery without surgery.8 However, no other papers have shown such successful outcomes. In other literature the rates of complete recovery have been reported to be as low as 39% and 50%.9,10 There is a group
of patients who experience ongoing pain and disability and for whom complete spontaneous resolution cannot be guaranteed. This is especially the case in those with systemic secondary causes such as diabetes.\textsuperscript{11} In addition, waiting for spontaneous recovery may not be deemed practical or acceptable as a management option to some patients, such as self-employed individuals.

Frozen shoulder typically affects the rotator interval and begins with thickening of the coracohumeral ligament.\textsuperscript{2} This manifests itself as early loss of external rotation, which is a classical sign. As the disease progresses, there is contraction of the glenohumeral capsule and thickening of the glenohumeral ligaments, with decrease in soft-tissue compliance.\textsuperscript{12} Such functional restriction is important for the differential diagnosis of shoulder pain. In the early stages of the disease, patients will report constant severe pain that is typically unguarded and has a strong nighttime component, which may prevent them from lying on the affected side. Nocturnal variation and sleep disturbance is one of Codman’s 12 original diagnostic criteria.\textsuperscript{1}

As the disease progresses, the pain typically resolves but disabling restriction of movement persists. The diagnosis is made clinically but radiographs must be obtained to differentiate frozen shoulder from alternative causes which lead to a restriction in external rotation, such as osteoarthritis or posterior dislocation. Case reports of misdiagnosed shoulder tumours mimicking the frozen shoulder are reported in the literature.\textsuperscript{13} MRI scans of patients with frozen shoulder will show thickening of the coracohumeral ligament and capsule at the rotator interval. The evidence suggests the extent of these MRI findings may correlate to the stage of disease, with synovial thickening predominantly seen earlier in the disease and capsular thickening predominantly in the later stages.\textsuperscript{14} Characteristic MRI features are illustrated in Figures 1 and 2.

Histological analysis from an intra-operative biopsy study demonstrated that the underlying pathological process was one similar to that of Dupuytren’s disease of the hand with fibroblastic proliferation and no evidence of inflammation.\textsuperscript{15} Patients with Dupuytren’s disease are reported to be eight times more likely to develop a frozen shoulder.\textsuperscript{16} Subsequent work has demonstrated features of chronic inflammation and used this to explain the severe pain experienced by patients and increased vascularity seen intra-operatively in patients with early disease.\textsuperscript{17}

The diabetic frozen shoulder

The diabetic frozen shoulder merits particular attention due to its disease profile, tending to be more severe in presentation and with inferior outcomes despite treatment.\textsuperscript{11} The underlying mechanism of frozen shoulder in
the diabetic patient is presumed to be due to collagen cross-linking mediated by hyperglycaemia, which then results in loss of tissue compliance.\textsuperscript{18} The clinical effect of this is limited joint mobility.\textsuperscript{19}

Frozen shoulder is reported to be almost twice as common in insulin-dependent diabetics compared with non-insulin-dependent diabetics.\textsuperscript{20} The same study showed that non-insulin-dependent diabetics on oral therapy are 1.5 times more likely to be affected by the disease than non-insulin-dependent diabetics on diet control. This study reported an increased association of frozen shoulder with prolonged duration of diabetic disease, i.e. more than ten years. They suggested that this may explain the increased incidence of frozen shoulder seen in insulin-dependent diabetics. Another study found a statistically significant difference in rates of frozen shoulder between 800 diabetic and 600 non-diabetic control patients, with 10.8% rate in the diabetic group compared with 2.3% in the control group.\textsuperscript{21} A higher proportion of the diabetic patients with frozen shoulder were insulin-dependent (36% versus 23%).

The literature supports inferior outcomes in the management of an insulin-dependent population, whether that be conservative or surgical.\textsuperscript{11} Thus, conservative treatment of the diabetic frozen shoulder is associated with inferior outcomes when compared with the non-diabetic population.

**Current treatment options**

*Injections and physiotherapy*

Initially frozen shoulder was predominantly thought to be an inflammatory condition, hence initial management has been with intra-articular injection of steroids and local anaesthetic into the glenohumeral joint and physiotherapy as first-line treatment. A randomised trial demonstrated superior outcomes of isolated treatment with injections over physiotherapy in primary frozen shoulder, with faster relief of symptoms in the injection group.\textsuperscript{22} However, it has also been demonstrated that there is a statistically significant benefit with the addition of physiotherapy after a glenohumeral joint injection.\textsuperscript{23} Despite the number of studies supporting glenohumeral injections in the management of frozen shoulder, significant heterogeneity in patient groups affects the conclusions that can be drawn. There is evidence of short-term benefits of oral steroids in the management of frozen shoulder but the benefits lasted less than six weeks.\textsuperscript{24} Other authors have demonstrated good outcomes in the early stages of frozen shoulder with oral steroids combined with neuropathic agents and a home exercise programme.\textsuperscript{25}

*Manipulation under anaesthesia (MUA)*

The intention of manipulation of the frozen shoulder under anaesthesia is to forcibly rupture the contracted capsule. MUA is often combined with intra-articular steroid injection to minimise the secondary inflammatory response in order to permit subsequent rehabilitation. However, the literature has called into question the benefit of intra-articular steroid injection after the procedure.\textsuperscript{26} Unique complications of MUA include fracture (glenoid, proximal humerus, clavicle) and brachial plexus injury.\textsuperscript{27} MUA may be performed in isolation or as an adjunct to arthroscopic arthrolysis. Short-term results within one year have been reported to be superior with combined MUA and arthroscopic arthrolysis compared with MUA alone, although after one year there was no difference.\textsuperscript{28}

The literature supports MUA as a treatment to accelerate recovery in frozen shoulder,\textsuperscript{29} but historically the literature has failed to support MUA as a treatment in diabetic patients, with poor short-term outcomes reported.\textsuperscript{30} However, more recent studies have demonstrated similar short- and long-term outcomes between non-diabetics and diabetic patients. These conclusions can only be made for non-insulin-dependent diabetics though, since insulin-dependent diabetics were excluded.\textsuperscript{31} A repeated procedure was necessary in 36% of diabetic patients.\textsuperscript{32}

*Arthroscopic arthrolysis (capsular release)*

Although various surgical techniques are available, a release of the anterior capsule and clearance of the rotator interval to include the superior and middle glenohumeral ligaments and the coracohumeral ligament is invariably performed in all reported studies. Variations on the technique include a spectrum of further releases, with some surgeons performing a full 360° release.\textsuperscript{33} As discussed previously some authors have combined arthroscopic arthrolysis with MUA as a result of the evidence from Sivardeen and colleagues demonstrating superior short-term outcomes.\textsuperscript{28} Literature comparing arthroscopic arthrolysis with MUA is lacking, suggesting the need for a high quality study to evaluate and compare these two main surgical options.\textsuperscript{34} Despite this, arthroscopic arthrolysis remains the preferred surgical option when managing frozen shoulder.\textsuperscript{35} It is anticipated that the currently recruiting multi-centre randomised United Kingdom Frozen Shoulder Trial (UK FROST), which is comparing structured physiotherapy versus manipulation under anaesthesia versus arthroscopic capsular release, will serve to further contribute to the literature base and answer some of the uncertainties regarding optimal management of the frozen shoulder.\textsuperscript{36} Previous literature has shown the results of arthroscopic arthrolysis in diabetic patients to be inferior to those in non-diabetics.\textsuperscript{37}

*Hydrodilatation (distension arthrography)*

Hydrodilatation is a non-surgical radiological intervention used in the management of frozen shoulder. Although therapeutic regimens will differ between units, common
secondary frozen shoulder. The technique involved a mixture of steroid (40 mg triamcinolone) and local anaesthetic (10 ml 0.5% bupivacaine), and varying volumes of saline to achieve full distension or rupture. Capsular rupture was recorded but the results were not published in the study. Diabetic patients were excluded. Primary outcomes included Shoulder Pain And Disability Index (SPADI) and Shoulder Disability Index (SDI) scoring. No control group was used in the study but the authors considered (for non-specified reasons) that due to the natural history of the disease, if a control group had been used then it would likely have shown similar outcomes to the hydrodilatation group at two years due to tendency for spontaneous improvement of the disease. The greatest magnitude of improvement was between three days and one week in terms of SPI scoring and between pre-treatment and three months in terms of SPADI scoring. The authors commented that most subjects demonstrated some functional deficit at final follow-up but referenced further literature to support a significant variation in the definition of ‘normal shoulder function’ in patients aged about 40 years.

A study by Clement et al provided post-hydrodilatation outcomes with a mean follow-up of 14 months. The authors included 53 procedures in 51 patients, 12 of whom were diabetic. The technique involved a mixture of steroid (40 mg or 80 mg triamcinolone depending on whether they were diabetic or not) and local anaesthetic (10 ml 1% lidocaine) with 40 ml saline. Capsular rupture was not documented. At one month post-procedure 55% of patients gained normal or near-normal shoulder function, and this result was maintained at final follow-up, with 63% of patients gaining normal or near-normal shoulder function as assessed by the Oxford Shoulder Score. One patient developed septic arthritis after hydrodilatation. Although they demonstrated similar outcomes in diabetic patients, the authors acknowledged the small sample as a potential bias in the results.

Table 1. Summary of the literature relating to hydrodilatation

| Study | Final number of patients | Regimen | Capsular rupture achieved | Follow-up | Outcome measure | Conclusion |
|-------|--------------------------|---------|---------------------------|-----------|-----------------|------------|
| Watson, 2007 (hydro) | 41 | 40 mg triamcinolone, 10 ml 0.5% bupivacaine. Varying saline | Not documented | 2 years | SPADI, SDI | Benefit maintained up to 2 years post-procedure |
| Clement, 2013 (hydro) | 39 | 40 mg or 80 mg triamcinolone, 10 ml 1% lidocaine. 40 ml saline | Not documented | 14 months | OSS | 55%/63% of patients had near-normal shoulder function at 1 month/final follow-up |
| Bell, 2003 (hydro) | 106 | 4 mg betamethasone, 2 ml 2% lidocaine. Varying saline | Yes | 3 years | Visual analogue, clinical ROM | 66% pain-free at 2 months. ROM improved 20–40° at 2 months. Worse in diabetics |
| Tveita, 2008 (hydro versus injection) | 39 (hydro) 37 (injection) | 20 mg triamcinolone, 4 ml 0.5% bupivacaine and 10 ml saline | Yes | 6 weeks | SPADI, clinical ROM | No difference between two groups |
| Quraishi, 2007 (hydro versus MUA) | 19 (hydro) 17 (MUA) | 30 mg triamcinolone, 2% lidocaine. Varying saline | Yes | 6 months | Visual analogue, constant scores | Patient satisfaction superior in hydro group (94% to 81%). No difference in constant scores |
| Trehan, 2010 (single hydro versus repeated hydro) | 22 | 80 mg triamcinolone, 10 ml 0.5% bupivacaine. 25 ml saline | Not documented | 15 months | OSS, SDQ-UK | No difference between single procedure versus repeated |

Notes: SPADI - Shoulder Pain And Disability Index. SDI - Shoulder Disability Index. OSS – Oxford Shoulder Score. ROM – range of movement. Hydro – hydrodilatation. SDQ-UK – Shoulder Disability Questionnaire UK Score

The role of hydrodilatation

A Cochrane review in 2008 demonstrated only silver-level evidence to support hydrodilatation as a treatment modality to improve short-term pain and function. This short-term benefit was only maintained up to three months. Data from five trials were included, although only one of these trials was low risk from bias. This highlights the deficiency in high-quality robust research available on hydrodilatation. The available literature is summarised in Table 1.

Currently the longest follow-up study investigating the outcomes of hydrodilatation is a two-year follow-up study on 41 patients undergoing hydrodilatation with an almost even distribution of patients with primary and secondary frozen shoulder. The technique involved a mixture of steroid (40 mg triamcinolone) and local anaesthetic (10 ml 1% lidocaine) with 40 ml saline. Capsular rupture was not documented. At one month post-procedure 55% of patients gained normal or near-normal shoulder function, and this result was maintained at final follow-up, with 63% of patients gaining normal or near-normal shoulder function as assessed by the Oxford Shoulder Score. One patient developed septic arthritis after hydrodilatation. Although they demonstrated similar outcomes in diabetic patients, the authors acknowledged the small sample as a potential bias in the results.
The study involving the largest number of patients reported on 109 frozen shoulders which were managed with hydrodilatation in 106 patients over a three-year period. In all, 15 patients included were diabetic (insulin status not stated). Their technique involved a mixture of steroid (4 mg betamethasone) and local anaesthetic (2 ml of 2% lidocaine), and varying volumes of saline required to achieve capsular rupture (between 10 ml and 55 ml). Patients were reviewed at two and four months. The primary outcome measures were pain scores on a visual analogue scale and clinical assessment of range of movement. No scoring systems were used. At two months, patients had a mean improvement of 30° of external rotation, 25° of abduction and 40° of elevation. Outcomes in diabetic patients showed a mean improvement of 30° of external rotation, 20° of abduction and 30° of elevation. Patients with severe loss of external rotation (< 15°) achieved the greatest improvement in range of movement, although still tended to have inferior ranges when compared with the patients without such profound external rotation loss. Patients with prolonged disease (> 12 months) achieved similar improvements when compared with those with a disease history of less than one year. On assessment of pain scoring, most patients reported their pain as moderate (47%) prior to the procedure and nil (66%) at two months. In the diabetic group, most patients reported their pain as moderate (67%) prior to the procedure and mild or nil (33%) each at two months. No further statistical analysis was performed. There were 29 repeat hydrodilatation procedures performed (22 non-diabetics, seven diabetics). Of these, five non-diabetics (23%) and two diabetics (29%) did not improve with the repeat hydrodilatation and went on to have arthroscopic arthrolysis, representing a failure rate of 5.5% in the original non-diabetic group and 13% in the original diabetic group (23% versus 29% failure rate after repeat procedure). The study stated that inferior outcomes of frozen shoulder in the diabetic patient generally appears to be seen also when the diabetic patient undergoes hydrodilatation.

There is currently no evidence in the literature to support superiority of surgical treatment for frozen shoulder over conservative treatment, but this may be due to small numbers of patients in small numbers of trials. Comparative studies between hydrodilatation and other treatment modalities are also lacking. Tveitå et al compared the outcomes of patients randomised to undergo hydrodilatation (20 mg triamcinolone with 4 ml 0.5% bupivacaine and 10 ml saline) with those randomised to fortnightly image-guided steroid injections (20 mg triamcinolone with 4 ml 0.5% bupivacaine) for six weeks. Diabetic patients were excluded. Capsular rupture was achieved in all but one patient in the hydrodilatation group. There were 39 patients in the hydrodilatation group and 37 in the injection group, and follow-up assessment was at six weeks from the last intervention. Patients were not allocated to physiotherapy but the study acknowledged that some patients were already enrolled in a physiotherapy regimen, a potential source of bias. Our standard practice is to begin physiotherapy within one week of hydrodilatation.

Quraishi et al randomised 17 patients to MUA and 19 patients to hydrodilatation; there were three insulin-dependent diabetics in each group. The technique used was the injection of steroid (30 mg triamcinolone) and local anaesthetic (2% lidocaine) mixture with varying volumes of saline required to rupture the capsule. The study demonstrated hydrodilatation as a successful treatment in the management of frozen shoulder with the success rates based upon patient satisfaction superior to manipulation under anaesthetic: 94% versus 81% at six-month final follow-up. Constant scores demonstrated a statistically significant improvement in both groups, but without a statistical significance between the two. They concluded that hydrodilatation attracted an added cost but a health benefit of avoiding a general anaesthetic, as well as reduced risk of surgical morbidity such as fracture or cuff injury.

There is no current literature comparing hydrodilatation with arthroscopic arthrolysis. However, there is evidence to suggest how many patients go on to require arthroscopic arthrolysis after suboptimal outcomes post-hydrodilatation.

Target hydrodilatation to the rotator interval has also been reported in the literature. This variation on the traditional technique has been investigated by one study using the novel approach in 22 patients, in whom they injected 21 ml of steroid (40 mg triamcinolone) and local anaesthetic mixture (10 ml 0.5% bupivacaine and 10 ml 1% lidocaine). Capsular rupture was not documented. Three patients were diabetic. Patients were followed up for four months, and at this time a statistically significant improvement in Oxford Shoulder Score compared with pre-operatively was reported from 13.6 to 36.5.

In our institution, patients who have achieved an improved response after hydrodilatation in terms of pain or function but still report ongoing deficit are offered a second hydrodilatation procedure. However, this is not standard practice and tends to be reserved for those who have initially responded well but have not fully benefited from the procedure. Trehan et al reported on 22 patients who underwent repeat hydrodilatation at six weeks. Their technique used the injection of steroid (80 mg triamcinolone) and local anaesthetic (10 ml 0.5% bupivacaine) mixture with 25 ml of saline. Capsular rupture during the procedure was not documented, neither was the patients’ diabetic status. They found that there was no statistically significant difference in the final Oxford Shoulder Score for patients undergoing single or repeat treatments.
Proposed mechanism of action of hydrodilatation

The mechanism of action of hydrodilatation is hotly debated. Most clinicians intuitively suggest that capsular rupture contributes to a mechanical resolution of the shoulder stiffness. However, it is well recognised that lack of capsular rupture during a hydrodilatation is not associated directly with failure of resolution of symptoms. Therefore, it is unclear whether the dilatation or slow capsular deformation aspect of the treatment is the key element rather than the capsular rupture. There is certainly evidence from studies examining the outcome of MUA to guide us. There seems to be no relationship between the clinician not feeling the tearing sensation during a MUA and the patient’s final outcome. In other words, whether or not the clinician feels the rupture of the capsule, the chance of recovery is the same. Therefore it is likely that there are intrinsic and extrinsic factors contributing to the resolution of frozen shoulder after treatment with hydrodilatation. One possible intrinsic mechanism is that the increased glycosaminoglycan concentration seen in the joint capsule in frozen shoulder promotes myofibroblast activity and this is reversed by the joint distension. We do not yet fully understand the contribution of the dilatation, steroid or the local anaesthetic to the successful outcome of hydrodilatation, therefore more research needs to be conducted to answer these remaining important questions.

Conclusion

Many cases of frozen shoulder are mild and will resolve with analgesics and physiotherapy. However, for patients who are not improving or in whom watchful waiting is not practical, hydrodilatation can be supported for short-term management. Diabetic patients must be counselled about the anticipated inferior outcomes when compared with the non-diabetic population. There is a role for hydrodilatation as a repeat procedure in patients with incomplete recovery but not as a standardised treatment plan.

This review highlights the need for high-quality controlled studies ensuring rigorous study design incorporating: (1) aetiology of the disease to differentiate between primary and secondary (extrinsic, intrinsic and systemic); (2) diabetic treatment regimen; (3) validated scoring systems and; (4) robust statistical analysis. Currently unanswered questions regarding the technical aspect of hydrodilatation include: (1) the role of capsular rupture and whether this is essential for a successful outcome; (2) the optimal hydrodilatation regimen in terms of volume and individual components and; (3) whether steroid is a key aspect in this regimen.

INDICATIONS FOR HYDRODILATATION FOR FROZEN SHOULDER

AUTHOR INFORMATION

1University Hospital of South Manchester NHS Foundation Trust, UK.

Correspondence should be sent to: Sophy Rymaruk, Department of Orthopaedic Surgery, University Hospital of South Manchester NHS Foundation Trust, Southmoor Rd, Wythenshawe, Manchester M23 9LT, UK.

Email: sophyrymaruk@hotmail.com

ICMJE CONFLICT OF INTEREST STATEMENT

Mr Peach is paid faculty on shoulder arthroplasty courses for Equinoxe shoulder prosthesis, activity outside the submitted work.

FUNDING STATEMENT

No benefits in any form have been received or will be received from a commercial party related directly or indirectly to the subject of this article.

LICENCE

© 2017 The author(s)

This article is distributed under the terms of the Creative Commons Attribution-Non Commercial 4.0 International (CC BY-NC 4.0) licence (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed.

REFERENCES

1. Codman EA. The Shoulder: Ruptures of the supraspinatus tendon and other lesions in or about the subacromial bursa. Boston, MA: Thomas Todd Co, 1934.
2. Sharma S, Jacobs L. Management of frozen shoulder — conservative vs surgical? Ann R Coll Surg Engl 2011;93:343.
3. Zuckerman JD, Rokito A. Frozen shoulder: a consensus definition. J Shoulder Elbow Surg 2011;20:322-325.
4. Sharma S, Jacobs L. The case for surgical treatment of the frozen shoulder. Ann R Coll Surg Engl 2011;93:343-344.
5. Bunker TD, Boyd M, Gallacher S, et al. Association between Propionibacterium acnes and frozen shoulder: a pilot study. Shoulder Elbow 2014;6:257-261.
6. Hakim AJ, Cherkas LF, Spector TD, MacGregor AJ. Genetic associations between frozen shoulder and tennis elbow: a female twin study. Rheumatology (Oxford) 2003;42:739-742.
7. Grey RG. The natural history of idiopathic frozen shoulder. J Bone Joint Surg [Am] 1978;60-A:556.
8. Vastamäki H, Kettunen J, Vastamäki M. The natural history of idiopathic frozen shoulder: a 2- to 27-year follow up study. Clin Orthop Relat Res 2012;470:1133-1143.
9. Reeves B. The natural history of the frozen shoulder syndrome. Scand J Rheumatol 1975;4:193-196.
10. Shaffer B, Tibone JE, Kerlan RK. Frozen shoulder. A long term follow up. J Bone Joint Surg [Am] 1992;74-A:738-746.
11. Griggs SM, Ahn A, Green A. Idiopathic adhesive capsulitis. A prospective functional outcome study of nonoperative treatment. J Bone Joint Surg [Am] 2000;82-A:1398-1407.
12. Petchprapa CN, Beltran LS, Jazrawi LM, et al. The Rotator Interval: A Review of Anatomy, Function, and Normal and Abnormal MRI Appearance. *AJR Am J Roentgenol* 2010;195:567–576.

13. Robinson D, Halperin N, Agar G, Alk D, Rami K. Shoulder girdle neoplasms mimicking frozen shoulder syndrome. *J Shoulder Elbow Surg* 2003;12:451–455.

14. Sofka CM, Ciavarra GA, Hannafin JA, Cordasco FA, Potter HG. Magnetic Resonance Imaging of Adhesive Capsulitis: Correlation with Clinical Staging. *HSS J* 2008;4:154–169.

15. Bunker TD, Anthony PP. The pathology of frozen shoulder. A Duperuytren-like disease. *J Bone Joint Surg (Br)* 1995;77-B:677–683.

16. Smith SP, Devaraj VS, Bunker TD. The association between frozen shoulder and Duperuytren’s disease. *J Shoulder Elbow Surg* 2001;10:149–151.

17. Hand GC, Athanasou NA, Matthews T, Carr AJ. The pathology of frozen shoulder. *J Bone Joint Surg (Br)* 2007;89-B:928–932.

18. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. *N Engl J Med* 1988;318:1315–1321.

19. Cambell RR, Hawkins SJ, Maddison PJ, Reckless JP. Limited joint mobility in diabetes mellitus. *Ann Rheum Dis* 1985;44:93–97.

20. Yian EH, Contreras R, Sodl JF. Effects of glycemic control on prevalence of diabetic frozen shoulder. *J Bone Joint Surg (Am)* 2012;94-A:919–923.

21. Bridqman JF. Periarthritis of the shoulder and diabetes mellitus. *Ann Rheum Dis* 1972;31:69–71.

22. van Windt DWM der, Koes BW, devillé W, et al. 1992;31:69–71.

23. Bridqman JF. Periarthritis of the shoulder and diabetes mellitus. *Ann Rheum Dis* 1972;31:69–71.

24. Buchbinder R, Hoving JL, Green S, et al. Effectiveness of corticosteroid injections versus physiotherapy for treatment of adhesive capsulitis of the shoulder: a randomised clinical trial. *BMJ* 1998;317:1292–1296.

25. Carette S, Moffet H, Tardif J, et al. Intraarticular corticosteroids, supervised physiotherapy, or a combination of the two in the treatment of adhesive capsulitis of the shoulder: a placebo-controlled trial. *Arthritis Rheum* 2003;48:829–838.

26. Kivimaki J, Pohjolainen T. Manipulation under anaesthesia for frozen shoulder: a randomised controlled trial. *BMJ* 2004;329:1460–1461.

27. Canbulat N, Eren I, Atalar AC, et al. Nonoperative treatment of frozen shoulder: oral glucocorticoids. *Int Orthop* 2015;39:249–254.

28. Kivimaki J, Pohjolainen T. Manipulation under anaesthesia for frozen shoulder with and without steroid injection. *Arch Phys Med Rehabil* 2002;83:1188–1190.

29. Birch R, Jessop J, Scott G. Brachial plexus palsy after manipulation of the shoulder. *J Bone Joint Surg (Br)* 1992;74:1825–1829.

30. Sivardeen KAZ, Paniker J, Drew S, Learmonth D, Massoud S. Frozen shoulder: Manipulation under anaesthesia or manipulation under anaesthesia and arthroscopic capsular release – which is the better treatment modality? *J Bone Joint Surg (Br)* 2012;94-B:135–139.

31. Olgivie-Harris DJ, Biggs DJ, Fitisalo DP, MacKay M. The resistant frozen shoulder. Manipulation versus arthroscopic release. *Clin Orthop Relat Res* 1995;319:238–248.

32. Jenkins EF, Thomas WC, Corcoran JP, et al. The outcome of manipulation under general anaesthesia for the management of frozen shoulder in patients with diabetes mellitus. *J Shoulder Elbow Surg* 2012;21:1492–1498.

33. Lofosse B, Boyle S, Kordasiewicz B, et al. Arthroscopic arthrolysis for recalcitrant frozen shoulder: a lateral approach. *Arthroscopy* 2012;28:916–923.

34. Grant JA, Schroeder N, Miller BS, Carpenter JE. Comparison of manipulation and arthroscopic capsular release for adhesive capsulitis: a systematic review. *J Shoulder Elbow Surg* 2013;22:1135–1145.

35. Kwaes TA, Charalambous CP. Surgical and non-surgical treatment of frozen shoulder. Survey on surgeons treatment preferences. *Muscles, Ligaments Tendons J* 2014;4:420–424.

36. No authors listed. ISRCTN Registry. http://www.controlled-trials.com/ISRCTN48804508 (date last accessed 14 September 2017).

37. Mehta SS, Singh HP, Pandey R. Comparative outcome of arthroscopic release for frozen shoulder in patients with and without diabetes. *Bone Joint J* 2014;96-B:1355–1358.

38. Rizk TE, Gavant ML, Pinals RS. Treatment of adhesive capsulitis (frozen shoulder) with arthrographic capsular distension and rupture. *Arch Phys Med Rehabil* 1994;75:803–807.

39. Buchbinder R, Green S, Youd JM, Johnston RV, Cumpton M. Arthrographic distension for adhesive capsulitis (frozen shoulder). *Cochrane Database Syst Rev* 2008;23.CD007005.

40. Watson L, Bialocerkowski A, Dalziel R, et al. Hydrodilatation (distension arthrography): a long-term clinical outcome series. *Br J Sports Med* 2007;41:167–173.

41. Roach KE, Budiman-Mak E, Songsrirudej N, Lerratanakul Y. Development of a shoulder pain and disability index. *Arthritis Care Res* 1991;4:149–149.

42. Brinker MR, Cuomo JS, Popham GJ, O’Connor DP, Barrack RL. An examination of bias in shoulder scoring instruments among healthy collegiate and recreational athletes. *J Shoulder Elbow Surg* 2002;11:463–469.

43. Clement RG, Ray AG, Davidson C, Robinson CM, Perks FJ. Frozen shoulder: lon-term outcome following arthrographic distension. *Acta Orthop Belg* 2013;79:368–374.

44. Dawson J, Fitzpatrick R, Carr A. Questionnaire on the perceptions of patients about shoulder surgery. *J Bone Joint Surg (Br)* 1996;78:593–600.

45. Bell S, Coghlan J, Richardson M. Hydrodilatation in management of shoulder capsulitis. *Australas Radiol* 2003;47:247–251.

46. Tveit EK, Bar‐G, Sesseng S, Juel NG, Bautz‐Holter E. Hydrodilatation, corticosteroids and adhesive capsulitis: A randomized controlled trial. *BMJ Musculoskeletal Disorder* 2008;9:53.

47. Quraishi NA, Johnston P, Baver B, Crowe M, Chakrabarti AJ. Thawing the frozen shoulder: A randomised trial comparing manipulation under anaesthesia with Hydrodilatation. *JRIS* 2007;89:1197–1200.

48. Yoong P, Duffy S, McKeen D, et al. Targeted ultrasound-guided hydrodilatation via the rotator interval for adhesive capsulitis. *Skeletal Radiol* 2015;44:703–708.

49. Trehan RK, Patel S, Hill AM, Curtis MJ, Connell DA. Is it worthwhile to offer repeat hydrodilatation for frozen shoulder after 6 weeks? *Int J Clin Pract* 2010;64:356–359.

50. Dedenhoff RM, Levy O, Wilson A, Copeland SA. Manipulation under anaesthesia for primary frozen shoulder: effect on early recovery and return to activity. *J Shoulder Elbow Surg* 2000;9:23–26.

51. Price FM, Levick JR, Mason RM. Changes in glycosaminoglycan concentration and synovial permeability at raised intra-articular pressure in rabbit knees. *J Physiol* 1996;495:821–833.